Tuesday, 17 November 2026Peptide medicines at the counter: price, coverage, supply, rules.

Reading as
What is this?
Gray marketUS

Lilly Hims deal puts Zepbound and Foundayo self pay prices inside the telehealth platform

Patients prescribed Zepbound or Foundayo on Hims & Hers will be able to get Lilly's self pay prices without leaving the platform, starting at $149 a month. Hims has pledged never to sell compounded copies of Lilly drugs, but membership fees and a start date were not published.

Editorial illustration for the story: Lilly Hims deal puts Zepbound and Foundayo self pay prices inside the telehealth platform
Illustration: Peptide Town. Cut-paper collage, not data.

Who feels it

  • Sellers Rethink

    Hims has pledged never to offer compounded copies of Lilly drugs, and Lilly says it will not partner with firms that sell copies.

  • Patients Adjust

    Self pay prices start at $149 for Foundayo and $299 for Zepbound on Hims, but any Hims membership fee is not published.

  • Prescribers Worth knowing

    Hims providers keep independent prescribing judgment under the agreement, Lilly said.

  • Pharmacies Worth knowing

    Another Lilly cash channel ships medicine to the home, outside the retail counter.

  • Payers Worth knowing

    More members may pay cash for branded obesity drugs as plans pull back on weight loss cover.

Eli Lilly and Hims & Hers said on November 6, 2026 that patients prescribed Zepbound or Foundayo on the Hims platform will be able to pay Lilly's self pay prices without leaving it. The Lilly Hims deal puts the entry price at $149 a month for the Foundayo pill and $299 a month for Zepbound, according to Lilly. It matters because Hims once sold compounded semaglutide at scale, and Lilly has taken sellers of unapproved copies to court. Neither company gave a start date, a membership fee or patient numbers.

What the Lilly Hims deal changes for patients

The mechanics are simple on paper. According to Lilly's own news release, a patient completes a consultation with a licensed provider on Hims, receives a prescription if that provider judges it appropriate, and gets the FDA approved medicine shipped home. Until now, Pharmaceutical Executive reported, Hims patients who wanted a Lilly obesity drug were sent off the site to LillyDirect, the drugmaker's own direct to consumer platform. Ilya Yuffa, who leads Lilly USA and Global Customer Capabilities, told Briefs that this extra step caused many patients to drop off. Lilly said Hims patients will see the same self pay prices that any other patient can get. The agreement covers two drugs: Zepbound, a tirzepatide injection, and Foundayo, Lilly's daily orforglipron pill.

Lilly frames the move as going where patients already are. "Our goal is to expand access as much as possible in the different channels," Yuffa told Briefs, adding that he estimates 30% to 40% of patients get obesity treatment through telehealth. That fits other research on how people reach these drugs; a USC and RAND preprint estimated that about 9 million US adults got GLP 1 drugs outside insurance and regular pharmacies. Hims is not Lilly's first virtual care partner, as Briefs noted the company already works with Ro and Weight Watchers. Investors reacted quickly. Hims shares were up 3.8% at 9:38 a.m. in New York on Friday, while Lilly's stock was flat, the outlet reported.

Zepbound self pay price and what it leaves out

The headline numbers are starting points, not flat fees. Lilly put the Zepbound self pay price at $299 a month and the Foundayo price at $149 a month, and Briefs described the Foundayo figure as its lowest tier, so higher strengths cost more. Self pay means the patient carries the cost, with no insurer in the loop. Lilly said patients on Hims will pay the same self pay prices available to any patient, so the deal changes the route to the medicine rather than the price. That route matters more as plans pull back; our reporting shows employers dropping GLP 1 coverage are pushing more of the bill onto workers, which sends more people toward cash channels like this one.

Lilly said patients on Hims will pay the same self pay prices available to any patient, so the deal changes the route to the medicine rather than the price.

Several costs and terms were not published. Lilly's release describes a Hims weight loss membership with round the clock access to a care team, nutrition guidance, regular clinical check ins and an online community, but it gives no fee for that membership. It also gives no start date, no list of states and no definition of which patients count as eligible. Neither company said how much Hims earns when a patient fills a Lilly prescription through its platform. Michael Cherny, an analyst at Leerink Partners, wrote that it is unclear whether the tie up grows Hims's market or simply adds a lower margin channel, Briefs reported. Until the fees are public, the true monthly cost to a patient using Hims remains unknown.

Compounded GLP 1 pledge and the gray market

The most important line in the release may be the one about copies. Lilly said Hims & Hers has never offered compounded copies of Lilly's GLP 1 medicines and has committed not to do so in future. Yuffa told Briefs that this commitment mattered in reaching the Lilly Hims deal. Lilly has said publicly that it will not partner with firms selling unapproved versions of its drugs, and it has sued such sellers. The pledge as described covers Lilly's products, and the release does not mention semaglutide. Hims's record there is mixed. Pharmaceutical Executive reported that in February 2026 Hims pulled a compounded semaglutide pill two days after launch, following legal pressure from Novo Nordisk and warnings from the FDA.

Novo has been here before. In June 2025 Novo walked away after eight weeks from a deal to offer branded Wegovy through Hims, saying the platform kept selling compounded semaglutide. Briefs reported that Hims reached a new arrangement with Novo earlier in 2026, and that Leerink's Cherny tied the Lilly agreement to Hims stopping personalized mass compounding. He called the news something that "feels both surprising and inevitable." As part of the new agreement, both companies also committed to protecting independent clinical decision making, so providers on Hims can keep prescribing what they judge right for each patient. For readers weighing a compounded GLP 1, the shift means one large platform now offers FDA approved Lilly drugs, while compounded products remain outside FDA approval and its quality checks.

WhenWhat happenedReported by
June 2025Novo ends its branded Wegovy partnership with Hims after about eight weeksPeptide Town
February 2026Hims pulls a compounded semaglutide pill two days after launchPharmaceutical Executive
2026, date not givenHims reaches a new arrangement with NovoBriefs
November 6, 2026Lilly and Hims announce self pay access to Zepbound and Foundayo on the platformEli Lilly

What to watch for telehealth weight loss drugs

Lilly has a sales reason to widen its reach. Briefs reported that Foundayo fell short of expectations in the latest quarter and that Lilly has stepped up marketing for the pill, including a new advertisement featuring Martha Stewart. Putting the $149 tier inside a large telehealth platform is one way to reach more cash paying patients, though neither company forecast how many will switch channels. Hims chief executive Andrew Dudum also pointed to Lilly's pipeline. "We'll be spending the next few years working with all of the expansions coming out, with drugs like reta in the coming year," he told Briefs, referring to retatrutide. That drug is still investigational and not approved, so any future role on Hims is a company hope, not a plan on the record.

For now, the Lilly Hims deal is a distribution change with clear prices and several open questions. Patients comparing telehealth weight loss drugs should check the full monthly cost, including any platform membership, and remember that cash payments sit outside their health plan. Prescribers on Hims keep their own judgment under the agreement, Lilly said. Payers and employers may see more members paying cash for branded drugs they no longer cover. Compounding sellers lose one more large partner, since Lilly says it will not work with firms that sell copies of its medicines. Quarterly results from both companies should show whether Zepbound and Foundayo volumes move through this channel. This story is research reporting, not medical advice, and it does not recommend any seller.

Conclusion

The Lilly Hims deal brings two FDA approved obesity drugs onto a platform that once sold compounded copies, at prices starting at $149 for Foundayo and $299 for Zepbound each month. It removes a step that Lilly says lost patients. The membership fee, start date and eligibility rules are still unpublished, so the real monthly cost for Hims users is not yet known.

Source Eli Lilly and Company news release, Nov 6 2026; Briefs; Pharmaceutical Executive

Spotted an error? Tell us through the contact form; we follow the corrections policy.